Zevra Therapeutics (NASDAQ:ZVRA) Rating Lowered to Hold at Wall Street Zen

Key Points

• Zevra Therapeutics has been downgraded from a "buy" to a "hold" rating by Wall Street Zen, following similar downgrades from other analysts.
• The stock has an average rating of "Moderate Buy" and a consensus price target of $24.00, despite an ongoing 4.7% increase in share price.
• Recent insider transactions show Director John B. Bode increasing his stake by purchasing 5,000 shares, indicating confidence in the company's future.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report released on Saturday.

A number of other equities analysts also recently commented on ZVRA. Zacks Research downgraded Zevra Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, August 18th. Weiss Ratings reissued a "sell (d)" rating on shares of Zevra Therapeutics in a report on Saturday, September 27th. HC Wainwright started coverage on shares of Zevra Therapeutics in a report on Wednesday, July 2nd. They issued a "buy" rating and a $26.00 target price on the stock. Cantor Fitzgerald lifted their price target on Zevra Therapeutics from $25.00 to $29.00 and gave the company an "overweight" rating in a report on Thursday, July 10th. Finally, Citigroup reaffirmed an "outperform" rating on shares of Zevra Therapeutics in a report on Wednesday, August 13th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $24.00.

Zevra Therapeutics Stock Up 4.7%

Shares of Zevra Therapeutics stock opened at $9.75 on Friday. The business has a 50-day moving average of $9.44 and a 200-day moving average of $8.98. The company has a debt-to-equity ratio of 0.52, a current ratio of 7.85 and a quick ratio of 7.81. The company has a market capitalization of $547.27 million, a PE ratio of -46.43 and a beta of 1.49. Zevra Therapeutics has a 1-year low of $6.19 and a 1-year high of $13.16.

Insider Transactions at Zevra Therapeutics

In other Zevra Therapeutics news, Director John B. Bode purchased 5,000 shares of the firm's stock in a transaction on Tuesday, August 19th. The shares were purchased at an average price of $9.16 per share, for a total transaction of $45,800.00. Following the completion of the transaction, the director owned 45,000 shares in the company, valued at $412,200. This represents a 12.50% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 2.40% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. grew its position in Zevra Therapeutics by 30.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company's stock worth $49,000 after purchasing an additional 1,280 shares in the last quarter. GAMMA Investing LLC grew its position in Zevra Therapeutics by 20,564.1% during the 1st quarter. GAMMA Investing LLC now owns 8,059 shares of the company's stock worth $60,000 after purchasing an additional 8,020 shares in the last quarter. Tower Research Capital LLC TRC grew its position in Zevra Therapeutics by 617.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company's stock worth $88,000 after purchasing an additional 8,552 shares in the last quarter. Creative Planning purchased a new position in Zevra Therapeutics during the 2nd quarter worth approximately $92,000. Finally, Fox Run Management L.L.C. purchased a new position in Zevra Therapeutics during the 2nd quarter worth approximately $99,000. Institutional investors and hedge funds own 35.03% of the company's stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.